81 results about "Mesenchyma" patented technology

Provided herein are methods and related compositions for enhancing or enhanced partial reprogramming of target cells in a subject in need thereof (e.g., a human subject suffering from or at risk of a disease), the method comprising administering a plurality of mesenchymal lineage progenitor or stem cells (MLPSCs), exosomes derived therefrom, or conditioned culture media derived therefrom to a subject that expresses or will express one or more reprogramming factors in a population of target cells, whereby a plurality of the target cells in the subject become partially reprogrammed, but not fully reprogrammed.

The present invention relates to CD73 + CD44 + , CD90 + A method for generating a population of mesenchymal stromal cells (MSCs) is provided. + CD44 + , CD90 + MSCs are used in methods to generate terminally differentiated osteogenic, adipogenic, and chondrogenic cells from pluripotent stem cells (PSCs), which involve the use of a single agent, a WNT signaling pathway activator (e.g., a GSK3β inhibitor), in adherent cultures of PSCs.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.

The invention relates to the technical field of biomedicine detection, and discloses a tumor cell marker detection system for predicting the activation state of intracellular protein kinase. Comprising a marker detection module used for qualitatively detecting epithelial cell markers, mesenchymal cell markers, cell polarity markers and extracellular matrix related markers in tumor cells; the data processing module is used for performing cross validation on an epithelial cell marker, a mesenchymal cell marker, a cell polarity marker and an extracellular matrix related marker; the dynamic weighting module is used for performing dynamic weighting on different markers based on a complex system theory, and endowing epithelial cadherin with a higher weight; and the judgment module is used for determining whether epithelial intercellular substance transformation occurs or not according to the dynamically weighted marker data, and predicting the activation state of intracellular phosphoinositide 3-kinase alpha and the invasiveness of tumor cells based on the determination result of the epithelial intercellular substance transformation.

The invention discloses a method for inducing fibroblasts to be reprogrammed into mesenchymal matrix-like cells (MLCs) by using small chemical molecules and application of the mesenchymal matrix-like cells (MLCs) in the anti-aging field. The invention discloses a set of specific chemical small molecule composition and an induction scheme thereof, which can be used for efficiently reprogramming fibroblasts from somatic cells into MLCs. Furthermore, the huge potential of the MLCs obtained by the method in anti-aging research is deeply explored, and the effect of the MLCs is proved to be obviously superior to that of umbilical cord mesenchymal stem cells in the aspects of reversing cell aging phenotypes and recovering tissue functions. The invention not only provides a new stem cell source strategy for avoiding the ethical and safety problems of the traditional reprogramming technology, but also lays a solid cell foundation for developing a novel, safe and effective anti-aging therapy based on cell transplantation or secreted factors.

The invention provides a nucleic acid molecule, a mesenchymal stromal cell for promoting angiogenesis and application thereof, and relates to the technical field of biomedicine, the nucleic acid molecule encodes an HGF protein, or encodes a VEGF165 protein and an HGF protein; the first signal peptide is used as a signal peptide of VEGF165 protein, and the second signal peptide is used as a signal peptide of HGF protein. Through a gene modification strategy, the MSC cell containing the nucleic acid molecule stably and efficiently expresses VEGF165 and / or HGF, and the expression quantity of the VEGF165 and / or HGF is obviously higher than that of the MSC without the nucleic acid molecule. The capability of promoting endothelial cell migration is realized; meanwhile, the cells can also remarkably promote proliferation and tube formation of HUVEC cells, and the strong angiogenesis promoting effect of the cells is further proved. The technical problem that in the prior art, nucleic acid molecules for expressing VEGF165 or / HGF cannot be stably and efficiently expressed is solved.

This invention relates to a method for expanding immune cells, the method comprising co-culturing the immune cells and at least one epithelial organoid, wherein the epithelial organoid comprises more epithelial cells than mesenchymal cells. Also provided are immune cells obtainable by the method, an in vitro population of innate lymphoid cells (ILCs) comprising at least 5×103 ILCs, pharmaceutical compositions and uses thereof.

This cell-based formulation contains SSEA-3-positive pluripotent stem cells derived from mesenchymal tissue of a living body or derived from cultured mesenchymal cells. This cell-based formulation is characterized in that the formulation is for administration to address diseases and / or post-acute sequelae caused by SARS-CoV-2 infection. The present invention makes it possible to provide a cell-based formulation that contains pluripotent stem cells and is used for treating and / or preventing SARS-CoV-2 infection-caused diseases such as pneumonia and pulmonary fibrosis and SARS-CoV-2 infection-caused post-acute sequelae such as olfactory dysfunctions.

The invention relates to the application of inhibition of transcription factor 4 (TCF4 / ITF2) in the treatment of cancer. This in particular in combination therapy in conjunction with an immunotherapeutic compound (such as for treating cancers poorly responding or refractive to immunotherapy). In particular, inhibition of TCF4 / ITF2 is capable of restoring response to immunotherapy such as immune checkpoint inhibitor therapy. Expression levels of TCF4 / ITF2 as well as levels of mesenchymal-like cancer cells in a cancer lesion are predictive of future response to immunotherapy early after initiation of the immunotherapy. Further part of the invention are methods of detecting mesenchymal-like cancer cells.

A method of increasing the chondrogenic potential mediated by TGFβ of a mesenchymal stromal cell (MSC) or a population of mesenchymal stromal cells (MSCs), comprising the step of increasing the amount of TGFβR1, and / or decreasing the amount of TGFβR2, and / or decreasing the amount of and / or ACVRL1 of the MSC or a population of mesenchymal stromal cells (MSCs).

Described herein are hydrogel compositions comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, hydroxypropyl methyl cellulose and a plurality of mesenchymal stromal cells.Additionally described herein are compositions for treatment, and methods for treatment of a disease, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, hydroxypropyl methyl cellulose and a plurality of mesenchymal stromal cells.

The present invention provides, as a technique that can be used for obtaining a skin organoid or a skin tissue structure that skillfully mimics the structure and function of the skin of a living body from stem cells, a skin organoid comprising cells that are derived from pluripotent stem cells and have the ability to differentiate into cells constituting the skin, the skin organoid having a lumen, the skin organoid having an epidermal cell layer comprising cells having the ability to differentiate into epidermis on the surface facing the lumen, and the skin organoid having a mesenchymal cell layer, on the outside of the epidermal cell layer, comprising cells having the ability to differentiate into dermis or subcutaneous tissue. The epidermal cell layer is configured by laminating, in this order from the lumen side, a granular layer comprising cells that express loricrin, a spinous layer comprising cells that express KRT10, and a basal layer comprising cells that express KRT5 and p63, and has hair pegs invaginating the mesenchymal cell layer.

The present invention provides a method for producing regenerated hair follicle primordium that allows production of regenerated hair follicle primordium more easily and in larger amounts compared to conventional production methods.A method for producing regenerated hair follicle primordium comprising a step of obtaining hair follicle primordium by culturing a first population of cells comprising epithelial cells and a second population of cells comprising mesenchymal cells while allowing them to be in contact is provided. The production method of the present invention is characterized in that at least either one of said first population of cells and said second population of cells has formed cell aggregates before said contact, and a culture support is not used when contacting the other population of cells with said cell aggregate.

The present application relates to the preparation and use of an anilino pyridine alkynyl compound in treating fibrotic diseases. Specifically, the compound of the present application has the structure of Formula I, wherein the definitions of each group and substituent are described in the specification. The present application also provides that the compound significantly improves the inhibitory effect of COL1A1 in the fibrotic epithelial-mesenchymal transition (EMT) model, and the compound has lower hepatotoxicity, and is expected to be used for preparing a drug for preventing and / or treating fibrotic diseases.

The invention provides a method of producing a population of CD73+ CD44+, CD90+ mesenchymal stromal cells (MSCs). The CD73+ CD44+, CD90+ MSCs are used in methods of generating terminally differentiated osteogenic, adipogenic and chondrogenic cells from pluripotent stem cells (PSCs). The differentiation method includes the use of a single agent, WNT signaling pathway activator such as a GSK3β inhibitor, used on adherent culture of PSCs.

The invention relates to the field of dermatology and cosmetology and can be used for regenerating wounds and preventing and correcting age-related skin changes, as well as for stimulating hair growth. The proposed composition contains as active ingredient the secretome of mesenchymal stromal cells (MSCs) derived from mammalian adipose tissue, the secretome being provided in an amount of 50-70 ‎μg / ml and being characterized by the presence of the following secretion products: FGF-2, KGF, TGF-β, PDGF, TGF-α, IGF-1, EGF, HGF, VEGF, G-CSF, GM-CSF, PGE2, ANG-1, ANG-2, MCP-1, MMPs, cysteine, tyrosine, arginine, glycine, histidine, isoleucine, lysine hydrochloride, methionine, phenylalanine, serine, threonine, tryptophan and valine. Also proposed is a method for producing the claimed composition, which includes techniques and conditions for harvesting and cultivating MSCs, making it possible to obtain a secretome having constituents effective for the treatment and regeneration of skin and hair.

This invention discloses the application of the CEMIP-ITGA5 axis as a target in the preparation of products that regulate epithelial-mesenchymal transition (EMT) and metastasis in lung adenocarcinoma, belonging to the fields of tumor molecular biology and precision medicine. Through TCGA-LUAD cohort bioinformatics analysis, immunohistochemical verification of clinical specimens, cell function experiments, and a nude mouse subcutaneous xenograft model, this invention discovers and confirms that the CEMIP-ITGA5 axis participates in regulating epithelial-mesenchymal transition, migration, invasion, and metastasis-related malignant progression in lung adenocarcinoma. Specifically, CEMIP positively regulates ITGA5 expression, thereby promoting EMT, proliferation, migration, invasion, and in vivo tumorigenesis in lung adenocarcinoma cells. Based on this, the present invention provides two applications: Firstly, by detecting the expression levels of the dual genes CEMIP and ITGA5, a kit for assessing the risk of epithelial-mesenchymal transition (EMT) and metastasis in lung adenocarcinoma can be prepared. The combined detection of CEMIP and ITGA5 can reflect the activation status of the CEMIP-ITGA5 axis at both the upstream regulatory molecule and downstream effector molecule levels, providing auxiliary molecular evidence for assessing EMT and metastasis-related risks in lung adenocarcinoma. Secondly, by targeting and inhibiting the expression or function of CEMIP and / or ITGA5, drugs can be prepared to inhibit epithelial-mesenchymal transition, migration, invasion, and metastasis-related malignant progression in lung adenocarcinoma, effectively reversing the epithelial-mesenchymal transition phenotype and inhibiting tumor malignant progression. This invention provides novel molecular targets and technical solutions independent of known signaling pathways for prognostic assessment and targeted therapy of lung adenocarcinoma.

The invention relates to the technical field of regenerative medicine application, in particular to a serum-free induction culture medium with definite components for promoting adipose tissue-derived cells to be differentiated into dermal papilla cells, an induction method and application. The invention relates to a method for promoting adipose tissue-derived cells to differentiate into dermal papilla cells, which is characterized in that the adipose tissue-derived cells are induced and cultured by using a serum-free induction culture medium, so that the adipose tissue-derived cells are differentiated into the dermal papilla cells. The formula of the serum-free induction culture medium comprises hepatocyte growth factors, hydrocortisone, bone morphogenetic protein 2, BIO and basic fibroblast growth factors. Based on the differentiation potential of adipose tissue-derived mesenchymal cells and the function maintenance mechanism of dermal papilla cells, a serum-free induction system with definite components is constructed, and directional differentiation is realized. According to the technical scheme, the technical problem that a method for inducing the adipose-derived mesenchymal cells to be directionally differentiated into the dermal papilla cells with the effective hair follicle regulation function is lacked in the prior art can be solved, and the method has ideal application and popularization potential.

The therapeutic needs of patients with IBD and / or related conditions or symptoms remain unmet, and new treatment options are needed. [Solution] This disclosure relates to a method for treating or preventing inflammatory bowel disease (IBD) in a subject in need thereof, comprising administering a composition comprising mesenchymal lineage progenitor or stem cell (MLPSC) to the subject.

The present disclosure relates to cellular therapy products comprising mesenchymal lineage precursor or stem cells and potency assay for these products. The present disclosure also relates to methods for treatment of immune or inflammatory disorders, and treatment or prevention of graft versus host disease (GVHD), or one or more symptoms associated with GVHD, by administration of mesenchymal lineage precursor or stem cells.

The present invention provides a method for producing regenerated hair follicle primordium that allows production of regenerated hair follicle primordium more easily and in larger amounts compared to conventional production methods.A method for producing regenerated hair follicle primordium comprising a step of obtaining hair follicle primordium by culturing a first population of cells comprising epithelial cells and a second population of cells comprising mesenchymal cells while allowing them to be in contact is provided. The production method of the present invention is characterized in that at least either one of said first population of cells and said second population of cells has formed cell aggregates before said contact, and a culture support is not used when contacting the other population of cells with said cell aggregate.

The application discloses a kind of fibroblast growth factor 2 and mesenchymal cell co-loaded freeze-dried collagen support and its preparation method and application, belong to the technical field of biomedical materials, by adding sulfated polysaccharide to collagen solution, it is formed freeze-dried collagen support containing sulfated polysaccharide by vacuum freeze-drying, it is combined with fibroblast growth factor 2 incubation, obtain the freeze-dried collagen support of loading fibroblast growth factor 2, again mesenchymal cell is inoculated in the freeze-dried collagen support of loading fibroblast growth factor 2, and the freeze-dried collagen support of fibroblast growth factor 2 and mesenchymal cell co-loading is prepared.The support obtained by the application can efficiently combine fibroblast growth factor 2, support the adhesion growth of mesenchymal cell simultaneously, promote mesenchymal cell to migrate to the inside of support, realize the uniform distribution of cell in support, and can promote angiogenesis, provide new and efficient carrier for cell transplantation treatment.

This disclosure relates to an MLPSC-mediated method for treating congenital heart disease. Such methods may be particularly suitable for treating subjects with hypoplastic left ventricular syndrome.

Provided in the present application is a bispecific antibody, which contains a first antigen-binding fragment against a human mesenchymal-epithelial transition factor (c-Met) and a second antigen-binding fragment against a human epidermal growth factor receptor (EGFR). In addition, further provided in the present application is the medical and biological use of the bispecific antibody.

The invention discloses application of CTSB as a congenital maxillofacial deformity diagnostic marker in preparation of a diagnostic reagent, and relates to the technical field of biomedicine.Early auxiliary diagnosis of congenital maxillofacial deformity is achieved by detecting the mRNA expression level or protein expression level of CTSB in a biological sample, and when the expression level is higher than that of a healthy control by two times or above, the CTSB can be used as the diagnostic marker for the congenital maxillofacial deformity. And the congenital maxillofacial deformity risk is prompted. The biological sample comprises blood, saliva, amniotic fluid or a palate embryo mesenchymal cell tissue sample. Early auxiliary diagnosis of congenital maxillofacial deformity can be realized by detecting the expression level of CTSB in a biological sample, and targeted therapeutic drugs can be developed by inhibiting the activity or expression of CTSB. The problems that in the prior art, congenital maxillofacial deformity diagnosis lags behind, and treatment lacks specificity are solved, and a new theoretical basis and a new technical means are provided for prevention and treatment of congenital maxillofacial deformity.

Compositions comprising a condensed mesenchymal cell body and a hydrogel are provided. The compositions may further include drugs or growth factors. The condensed mesenchymal cell body may include a connective tissue cell, or even a progenitor cell capable of producing connective tissue extracellular matrices such collagen and glycosaminoglycan. Also provided are methods of treating connective tissue defects, cartilage injury, and cartilage degradation.

This invention provides the application of MYOF as a biomarker for mesenchymal glioma (GLM) stem cells, belonging to the field of biomedical technology. Through in-depth mining of tumor databases and analysis of clinical samples, this invention is the first to discover the high expression of MYOF in GBM tissues. Compared with NPC, NSTC, and non-mesenchymal glioma stem cells, MYOF is specifically highly expressed in GLM stem cells. High MYOF expression promotes the proliferation, spheroidization, and self-renewal capacity of MES-GSCs. Therefore, inhibiting MYOF expression in MES-GSCs can effectively inhibit the proliferation, spheroidization, and self-renewal capacity of MES-GSCs, thereby inhibiting GBM progression. The MYOF-based detection products and targeted therapeutic drugs provided by this invention offer new ideas for the early diagnosis, malignancy assessment, precision treatment, and prognostic evaluation of GBM.

The therapeutic needs of patients with IBD and / or related conditions or symptoms remain unmet, and new treatment options are needed. [Solution] This disclosure relates to a method for treating or preventing inflammatory bowel disease (IBD) in a subject in need thereof, comprising administering a composition comprising mesenchymal lineage progenitor or stem cell (MLPSC) to the subject.